Key Highlights

  • CERS was down 7.20% at USD 2.19 in pre-market trading on November 3, 2026.
  • Third-quarter 2026 total Revenue was USD 64.0 million, up 6% from USD 60.2 million.
  • Product revenue rose 10% to USD 57.7 million, with product gross Margin at 52.4%.
  • The company announced positive topline results from its Phase 3 RedeS trial on November 2, 2026.
  • Cash, cash equivalents and short-term investments were USD 57.1 million at September 30, 2026.

What moved the stock in pre-market trading (down USD 0.1699, 7.20%)

Cerus (NASDAQ:CERS) was down 7.20% at USD 2.19 in pre-market trading on November 3, 2026. The implied Monday November 2, 2026 close is about USD 2.36 (calculated).

The company released third-quarter 2026 results and announced positive topline data from the RedeS trial on November 2, 2026, with a conference call at 4:30 p.m. Eastern.

Third-quarter results in detail

According to a company press release dated November 2, 2026, total revenue was USD 64.0 million and product revenue was USD 57.7 million. Government contract revenue fell to USD 6.3 million from USD 7.5 million a year earlier.

Product Gross Profit was USD 30.3 million, and the margin narrowed to 52.4% from 53.4%. Operating expenses were USD 36.2 million, including USD 14.3 million for research and development. The net loss attributable to Cerus was USD 0.6 million, and adjusted EBITDA was USD 5.7 million, compared with USD 5.0 million a year earlier.

The company guided full-year 2026 product revenue to USD 229 million to USD 231 million.

Business background and the RedeS trial

Cerus, based in Concord, California, sells the INTERCEPT Blood System, which is designed to reduce pathogens in donated platelets and plasma. The company also markets INTERCEPT Fibrinogen Complex, which is FDA-approved for fibrinogen deficiency.

The red blood cell version of the system is under regulatory review in Europe and in late-stage clinical development in the United States. The company said the Phase 3 RedeS trial produced positive topline results, while cautioning that findings may change after the full analysis, including secondary endpoints. The release did not include numerical trial data in the material reviewed.

Balance sheet and risks

Cash, cash equivalents and short-term investments were USD 57.1 million at September 30, 2026, down from USD 82.9 million at December 31, 2025. The company reported a USD 35.0 million term Loan and USD 28.5 million drawn on a revolver, with USD 16.5 million more available subject to a borrowing base.

Trading below USD 5, CERS is a penny stock, and such shares can be volatile and thinly traded in extended hours, which means early prices may not hold into the regular session.

What to watch next

Investors will look for the full RedeS data set, the timing of any regulatory submission for the red blood cell system and fourth-quarter product revenue against the guided range.